China's First MVIV + BATMAN: West China Hospital's Dual Innovation Saves 72-Year-Old from Open-Heart Redo
When the First Heart Surgery Wears Out — and a Second One Is Too Dangerous
Biological heart valves don't last forever. After 10-15 years, the tissue degenerates — stiffening, calcifying, and eventually failing. For patients who received a biological mitral valve replacement years ago, this creates a daunting prospect: another open-heart surgery, through the same scarred chest, with all the risks amplified by age, adhesions, and weakened cardiac function.
A 72-year-old woman at West China Hospital (Sichuan University) faced exactly this situation — but with an added complication that made even the transcatheter alternative potentially lethal.
The solution her surgical team devised had never been performed in China before.
The Patient's Dilemma
The patient had undergone open-chest biological mitral valve replacement 7 years earlier. Now, the biological valve had deteriorated — a condition called structural valve degeneration (SVD) — with severe regurgitation causing progressive heart failure symptoms: chest tightness, shortness of breath, and declining exercise tolerance.
Complicating matters significantly, she also had severe pulmonary hypertension — elevated pressure in the lung arteries that dramatically increases the risk of any cardiac procedure.
A repeat open-heart surgery would require:
| Requirement | Risk for This Patient |
|---|---|
| Full sternotomy (chest opening) | Dense adhesions from previous surgery; high bleeding risk |
| Cardiopulmonary bypass | Severe pulmonary hypertension makes weaning off bypass dangerous |
| General anesthesia (prolonged) | Age 72 with compromised cardiac function |
| Extended ICU recovery | High risk of respiratory failure post-operatively |
The team led by Professor Hu Jia, Chief Physician of Cardiac and Macrovascular Surgery, determined that a transcatheter approach — replacing the failed valve through a catheter without opening the chest — was the safer path. But there was a catch.
The Hidden Danger: Left Ventricular Outflow Tract Obstruction
Pre-operative 3D reconstruction revealed a critical anatomical problem: the patient's cardiac geometry meant that simply deploying a new valve inside the old one (a standard "valve-in-valve" or MVIV procedure) would push the native anterior mitral leaflet into the left ventricular outflow tract (LVOT) — the channel through which blood exits the heart.
LVOT obstruction is immediately life-threatening. The heart can no longer eject blood effectively, leading to cardiogenic shock and death within minutes if not resolved.
This anatomical risk rules out simple MVIV for many patients — and historically sent them back to the operating room for open surgery despite the elevated risks.
The Innovation: MVIV + BATMAN
Professor Hu Jia's team, in collaboration with anesthesiologist Professor Song Haibo, devised an unprecedented combined approach:
MVIV (Mitral Valve-in-Valve) — Delivering a new transcatheter valve through the femoral vein, across the atrial septum, and into the failing biological valve — all without opening the chest.
BATMAN (Balloon-Assisted Translocation of the Mitral Anterior Leaflet to Neutralize LVOT obstruction) — Before deploying the new valve, a specialized balloon catheter was used to physically displace the anterior mitral leaflet away from the outflow tract, expanding the LVOT space and eliminating the obstruction risk at its source.
This combined MVIV + BATMAN technique addressed both problems simultaneously:
- Replace the failed valve without open-heart surgery
- Prevent LVOT obstruction that would otherwise make transcatheter replacement impossible
The Procedure
The entire operation was performed via the femoral vein — a puncture in the groin, with the catheter navigated through the venous system, across the interatrial septum, and into the mitral position.
- No chest incision
- No cardiopulmonary bypass
- No cardiac arrest
Post-deployment imaging confirmed: new valve functioning normally, zero LVOT obstruction, and immediate improvement in cardiac output.
Transcatheter vs. Repeat Open-Heart Surgery
| Factor | MVIV + BATMAN (West China) | Repeat Open-Heart Surgery |
|---|---|---|
| Incision | Femoral vein puncture (groin) | Full sternotomy (20-25 cm chest incision) |
| Cardiopulmonary bypass | Not required | Required (high-risk with pulmonary hypertension) |
| Adhesion risk | None — no chest entry | Extremely high from previous surgery |
| Procedure time | Shorter | 4-6+ hours |
| ICU stay | Minimal or none | Days to weeks |
| Recovery | Days | Weeks to months |
| LVOT obstruction risk | Eliminated by BATMAN technique | Managed surgically (adds complexity) |
Why This Matters for International Patients
Biological valve degeneration is a growing global problem. As more patients receive tissue valves (chosen because they avoid lifelong blood thinners), more will eventually face the question: what happens when the valve wears out?
For many — especially elderly patients, those with pulmonary hypertension, or those with heavily scarred chests from previous surgery — repeat open-heart surgery carries unacceptable risk. The MVIV + BATMAN combination offers these patients a way out that didn't exist before.
Mitral Valve Surgery Cost: China vs Western Countries
| Procedure | China (West China Hospital) | United States |
|---|---|---|
| Transcatheter mitral valve-in-valve (MVIV) | $25,000 - $45,000 | $100,000 - $200,000 |
| MVIV + BATMAN (combined) | $30,000 - $50,000 | Not widely available |
| Repeat open mitral valve replacement | $18,000 - $35,000 | $80,000 - $180,000 |
| Cardiac ICU (per day) | $500 - $1,200 | $5,000 - $15,000 |
China prices include procedure, transcatheter valve device, hospital stay, and post-operative monitoring.
About West China Hospital Cardiac Surgery
West China Hospital is consistently ranked among China's top 3 hospitals, and its cardiac surgery program is a national leader in structural heart interventions:
- Professor Hu Jia leads the cardiac and macrovascular surgery division with extensive experience in transcatheter valve therapies
- 4,300+ beds — One of the world's largest single-site hospitals
- Affiliated with Sichuan University — a top-10 Chinese university
- Located in Chengdu, with direct international flights from major global cities
Has your biological heart valve started failing? Don't assume repeat open-heart surgery is your only option. Explore advanced cardiac treatment in China →
Need a second opinion on valve disease or structural heart conditions? Request a free cardiac consultation →
